Biogen to Acquire Apellis Pharmaceuticals in a $5.6 Billion Deal
Biogen Inc. (BIIB) entered a merger agreement on March 31, 2026, to acquire Apellis Pharmaceuticals, Inc. (APLS) in a deal valued at $5.6 billion. Deal Structure: Biogen will…
Written byAsif SuriaSource: InsideArbitrage
Biogen Inc. (BIIB) entered a merger agreement on March 31, 2026, to acquire Apellis Pharmaceuticals, Inc. (APLS) in a deal valued at $5.6 billion. Deal Structure: Biogen will commence a tender offer to acquire all of the outstanding shares of Apellis for $41 per share in cash and a non-transferable CVR per share. The cash